Results of multivariate analyses comparing graft failure, GVHD, and TRM according to donor-recipient mismatch patterns for non–T-cell–depleted sibling or parent transplantation
| Outcome . | Patients at risk . | Combined model sibling–parent RR (95% CI) . | P . | Parents-only model RR (95% CI) . |
|---|---|---|---|---|
| Graft failure3-150,3-151 | ||||
| NIMA (sibling donor) | 63 | 1.0 | — | — |
| NIPA (sibling donor) | 67 | 0.61 (0.25-1.53) | .30 | — |
| Mother donor | 79 | 0.86 (0.39-1.89) | .70 | 1.0 |
| Father donor | 55 | 1.12 (0.50-2.50) | .78 | 0.38 (0.09-1.59) |
| Acute grades 2 to 4 GVHD3-152,3-153 | ||||
| NIMA (sibling donor) | 63 | 1.0 | — | — |
| NIPA (sibling donor) up to 7 d | 69 | 0.21 (0.03-1.61) | .13 | — |
| NIPA (sibling donor) more than 7 d | — | 1.86 (1.15-3.05) | .02 | — |
| Mother donor | 79 | 1.88 (1.15-3.05) | .01 | 1.0 |
| Father donor | 57 | 2.20 (1.32-3.66) | .003 | 1.17 (0.75-1.81) |
| Chronic GVHD3-154,3-159 | ||||
| NIMA (sibling donor) | 63 | 1.0 | — | — |
| NIPA (sibling donor) | 69 | 1.76 (0.90-3.44) | .10 | — |
| Mother donor | 79 | 2.32 (1.22-4.42) | .01 | 1.0 |
| Father donor up to 4 mo | 57 | 4.11 (1.89-8.95) | .0004 | 2.44 (1.12-5.34) |
| Father donor more than 4 mo | — | 0.74 (0.16-3.28) | .69 | 0.40 (0.08-1.70) |
| TRM3-160 | ||||
| NIMA (sibling donor) | 63 | 1.0 | — | — |
| NIPA (sibling donor) | 69 | 1.30 (0.73-2.31) | .38 | — |
| Mother donor | 79 | 2.02 (1.19-3.43) | .009 | 1.0 |
| Father donor | 57 | 1.92 (1.07-3.45) | .03 | 0.95 (0.56-1.56) |
| Outcome . | Patients at risk . | Combined model sibling–parent RR (95% CI) . | P . | Parents-only model RR (95% CI) . |
|---|---|---|---|---|
| Graft failure3-150,3-151 | ||||
| NIMA (sibling donor) | 63 | 1.0 | — | — |
| NIPA (sibling donor) | 67 | 0.61 (0.25-1.53) | .30 | — |
| Mother donor | 79 | 0.86 (0.39-1.89) | .70 | 1.0 |
| Father donor | 55 | 1.12 (0.50-2.50) | .78 | 0.38 (0.09-1.59) |
| Acute grades 2 to 4 GVHD3-152,3-153 | ||||
| NIMA (sibling donor) | 63 | 1.0 | — | — |
| NIPA (sibling donor) up to 7 d | 69 | 0.21 (0.03-1.61) | .13 | — |
| NIPA (sibling donor) more than 7 d | — | 1.86 (1.15-3.05) | .02 | — |
| Mother donor | 79 | 1.88 (1.15-3.05) | .01 | 1.0 |
| Father donor | 57 | 2.20 (1.32-3.66) | .003 | 1.17 (0.75-1.81) |
| Chronic GVHD3-154,3-159 | ||||
| NIMA (sibling donor) | 63 | 1.0 | — | — |
| NIPA (sibling donor) | 69 | 1.76 (0.90-3.44) | .10 | — |
| Mother donor | 79 | 2.32 (1.22-4.42) | .01 | 1.0 |
| Father donor up to 4 mo | 57 | 4.11 (1.89-8.95) | .0004 | 2.44 (1.12-5.34) |
| Father donor more than 4 mo | — | 0.74 (0.16-3.28) | .69 | 0.40 (0.08-1.70) |
| TRM3-160 | ||||
| NIMA (sibling donor) | 63 | 1.0 | — | — |
| NIPA (sibling donor) | 69 | 1.30 (0.73-2.31) | .38 | — |
| Mother donor | 79 | 2.02 (1.19-3.43) | .009 | 1.0 |
| Father donor | 57 | 1.92 (1.07-3.45) | .03 | 0.95 (0.56-1.56) |
Bu indicates busulfan; Cy, cyclophosphamide; TBI, total body irradiation; MTX, methotrexate; RR, relative risk; CI, confidence interval.
Model stratified by use of methotrexate for GVHD prophylaxis.
Other significant variables include: use of BuCy vs CyTBI for conditioning (RR, 2.44; 95% CI, 1.22-4.91; P = .01); Karnofsky performance score < 90% vs ≥ 90% (RR, 0.50; 95% CI, 0.31-2.29; P = .04).
Model stratified by disease stage before transplantation. Time-dependent covariate, such that the relative risk of AGVHD differs between NIMA and NIPA sibling before and after 7 days after transplantation.
Other significant variable, includes use of BuCy vs CyTBI for conditioning (RR, 0.47; 95% CI, 0.25-0.89; P = .02).
Pairwise comparison: NIPA sibling (early) vs mother donor (P = .03); NIPA sibling (late) vs mother (P = .96); NIPA sibling early vs father (P = .02); NIPA sibling late vs father (P = .48).
Time-dependent covariate, such that the relative risk of chronic GVHD differs between NIMA and father as donor before and after 4 months after transplantation. Other significant variables include class 1 antigen mismatch vs class 1 and 2 mismatch (RR, 0.44; 95% CI, 0.24-0.84; P = .01); class 2 antigen mismatch vs class 1 and 2 mismatch (RR, 0.32; 95% CI, 0.13-0.80; P = .02).
Pairwise comparison: NIPA sibling vs mother donor (P = .05); NIPA sibling vs father donor early (P = .001); NIPA sibling vs father donor late (P = .18).
Other significant variables include donor age ≥ 35 y (RR, 2.47; 95% CI, 1.36-4.50; P = .003); advanced disease stage at transplantation (RR, 1.89; 95% CI, 1.18-3.02;P = .008); transplantation year 1989 or later (RR, 0.59; 95% CI, 0.40-0.87; P = .009).